Use of CpG oligodeoxynucleotides as immune adjuvants.
Synthetic oligodeoxynucleotides (ODNs) containing unmethylated CpG motifs directly stimulate human B cells and plasmacytoid dendritic cells (pDCs), thereby promoting the production of T helper 1 (Th1) and pro-inflammatory cytokines and the maturation/activation of professional antigen-presenting cells. These activities enable CpG ODNs to act as immune adjuvants, accelerating and boosting antigen-specific immune responses by 5-500-fold. These effects are optimized by maintaining close physical contact between the CpG DNA and the immunogen. Animal challenge models establish that protective immunity can be accelerated and magnified by coadministering CpG DNA with vaccines. Ongoing clinical studies indicate that CpG ODNs are safe and well tolerated when administered as adjuvants to humans, and in some cases, they increase vaccine-induced immune responses.
Klinman
Dennis M
DM
Section of Retroviral Immunology, Division of Viral Products, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, MD 20892, USA. klinman@cber.fda.gov
Currie
Debra
D
Gursel
Ihsan
I
Verthelyi
Daniela
D
D000276:Adjuvants, Immunologic / Q000494:pharmacology*; D000818:Animals; D006801:Humans; D007117:Immunization, Secondary; D009838:Oligodeoxyribonucleotides / Q000494:pharmacology*; D010957:Plasmids / Q000235:genetics / Q000276:immunology; D019444:Vaccines, DNA / Q000276:immunology*
D000276:Adjuvants, Immunologic; C408982:CPG-oligonucleotide; D009838:Oligodeoxyribonucleotides; D019444:Vaccines, DNA